Endoscopic Ultrasonography-Guided Ethanol Ablation for Small Pancreatic Neuroendocrine Tumors: Results of a Pilot Study

Do Hyun Park; Jun-Ho Choi; Dongwook Oh; Sang Soo Lee; Dong-Wan Seo; Sung Koo Lee; Myung-Hwan Kim

doi:10.5946/ce.2015.48.2.158

Articles

Page Path: HOME > Clin Endosc > Volume 48(2); 2015 > Article

Original Article Endoscopic Ultrasonography-Guided Ethanol Ablation for Small Pancreatic Neuroendocrine Tumors: Results of a Pilot Study: Do Hyun Park¹, Jun-Ho Choi², Dongwook Oh¹, Sang Soo Lee¹, Dong-Wan Seo¹, Sung Koo Lee¹, Myung-Hwan Kim¹; Clinical Endoscopy 2015;48(2):158-164.
DOI: https://doi.org/10.5946/ce.2015.48.2.158
Published online: March 27, 2015

¹Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

²Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.

Correspondence: Do Hyun Park. Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3194, Fax: +82-2-485-5782, dhpark@amc.seoul.kr

Do Hyun Park and Jun-Ho Choi contributed equally to this work as first authors.

• Received: April 7, 2014 • Revised: July 9, 2014 • Accepted: July 22, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

7,861 Views
117 Download
67 Web of Science
64 Crossref
74 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
Acknowledgments
Acknowledgments
NOTES
REFERENCES

Abstract

Background/Aims
Endoscopic ultrasonography (EUS)-guided ethanol ablation is gaining popularity for the treatment of focal pancreatic lesions. The aim of this study was to evaluate the safety, feasibility, and treatment response after EUS-guided ethanol injection for small pancreatic neuroendocrine tumors (p-NETs).
Methods
This was a retrospective analysis of a prospectively collected database including 11 consecutive patients with p-NETs who underwent EUS-guided ethanol injection.
Results
EUS-guided ethanol injection was successfully performed in 11 patients with 14 tumors. The final diagnosis was based on histology and clinical signs as follows: 10 non-functioning neuroendocrine tumors and four insulinomas. During follow-up (median, 370 days; range, 152 to 730 days), 10 patients underwent clinical follow-up after treatment, and one patient was excluded because of loss to follow-up. A single treatment session with an injection of 0.5 to 3.8 mL of ethanol resulted in complete responses (CRs) at the 3-month radiologic imaging for seven of 13 tumors (response rate, 53.8%). Multiple treatment sessions performed in three tumors with residual viable enhancing tissue increased the number of tumors with CRs to eight of 13 (response rate, 61.5%). Mild pancreatitis occurred in three of 11 patients.
Conclusions
EUS-guided ethanol injection appears to be a safe, feasible, and potentially effective method for treating small p-NETs in patients who are poor surgical candidates.
Keywords: Endosonography; Ethanol; Ablation; Neuroendocrine tumors

INTRODUCTION

Pancreatic neuroendocrine tumors (p-NETs) are fairly rare, accounting for 1% to 2% of primary pancreatic malignancies.1 The incidence and prevalence of p-NETs have increased substantially recently, possibly because of the widespread use of advanced endoscopic and radiological imaging.2 The clinical presentation of p-NETs varies strikingly in terms of symptoms and outcomes.3 The overall 5-year survival rate ranges from 30% for nonfunctioning neuroendocrine tumors to 97% for benign insulinomas.4 Treatment for p-NETs should be highly tailored on the basis of the extent of disease, associated symptoms, presence of extrahepatic metastasis, and patient performance status. For patients with resectable tumors >2 cm, surgical resection is the standard of care.5 On the contrary, for those with nonfunctioning small (<2 cm) p-NETs, for which no study has revealed a survival benefit of surgery,5,6 the benefit of surgery must be balanced against operative morbidity and mortality.

Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) for pancreatic lesions is considered a minimally invasive diagnostic tool, and EUS-guided pancreatic injection of ethanol or other chemotherapeutic agents has been reported with few procedural complications.7 Ethanol is the most commonly used ablative agent for focal pancreatic and hepatic lesions.7,8,9 EUS-guided ethanol ablation has been recently proposed for the treatment of p-NETs.10,11,12,13 Levy et al.12 reported that ultrasonography-guided ethanol ablation for insulinoma is technically feasible and safe, and symptomatic improvement was achieved in all eight patients (100%). However, these studies only included a small number of patients with functioning insulinomas. The aim of this pilot study was to investigate the safety, feasibility, and treatment response after EUS-guided ethanol injection for small p-NETs including nonfunctioning endocrine tumors.

MATERIALS AND METHODS

Data source and study population

Between February 2012 and February 2013, patients with suspicious p-NETs on imaging results and/or clinical features who were referred for differential diagnosis and management were enrolled in this study using specific inclusion and exclusion criteria. The diagnosis of p-NET was based on clinical and characteristic imaging findings, such as well-demarcated and hypervascular mass lesions in the pancreas (Fig. 1A). The presence of a p-NET was further confirmed by p-NET cytology or histopathology from a core biopsy specimen. A diagnosis of insulinoma was suspected in patients with symptomatic fasting hypoglycemia, which includes: (1) symptoms and signs of hypoglycemia, (2) concomitant plasma glucose level of ≤45 mg/dL, and (3) reversibility of symptoms with glucose administration. A total of 11 patients were enrolled in the study, and they subsequently underwent EUS-guided fine-needle injection of 99% pure ethanol. The study was approved by the Institutional Review Board of the Asan Medical Center (Seoul, Korea), and written informed consent was obtained from all patients.

The inclusion criteria were as follows: (1) a p-NET <2 cm in diameter, (2) low suitability for surgery (multifocal location, American Society of Anesthesiologist physical status classification grade III or IV), (3) refusal of surgery, and (4) follow-up for >3 months after EUS-guided ethanol injection. The exclusion criteria were as follows: (1) refusal to participate in the study, (2) overt carcinomas, (3) bleeding tendency (prothrombin time >1.5 international normalized ratio or a platelet count <50,000/µL), (4) age <18 years, (5) pregnancy, and (6) active acute pancreatitis.

Procedures

EUS-guided intervention

All EUS procedures were performed after the patient was consciously sedated using midazolam and meperidine. To prevent acute pancreatitis and infection, a prophylactic antibiotic (ceftizoxime or ceftriaxone) and antiprotease prophylaxis (gabexate mesylate 300 mg in saline solution 500 mL, starting before the procedure and continuing for 24 hours) were intravenously administered.

The procedures were performed according to the following scheme:

(1) Step 1: diagnostic contrast-enhanced harmonic EUS (CEH-EUS) with FNA was performed to confirm the neuroendocrine nature of the tumor. A curvilinear array echoendoscope (GF-UCT 240-AL 10; Olympus Medical System, Tokyo, Japan) was used to perform both CEH-EUS and FNA. The ultrasound processor was the Aloka Prosound Alpha 10 (Aloka Co., Ltd., Tokyo, Japan), which incorporates dedicated software for CEH-EUS. After a complete EUS examination of the pancreas in B-mode, the echoendoscope was switched to the CEH-EUS mode. SonoVue (Bracco, Milan, Italy) was used as a contrast agent. A bolus infusion of 2.5 mL of SonoVue into an antecubital vein was followed by injection of 10 mL of saline solution. EUS-FNA was performed using a 22-gauge needle (EchoTip Ultra or ProCore; Cook Endoscopy, Winston Salem, NC, USA).

(2) Step 2: EUS-guided ethanol injection: the FNA needle was introduced into the tumor under real-time EUS. The optimal volume of ethanol (99%) injected into the tumor was determined according to the size of the tumor and calculated by computer estimation of areas on each axial image using EUS software permitting volume calculation (Fig. 1B). Then, the needle was advanced into the tumor (Fig. 1C), and the injections were repeated until the hyperechoic blush extended to the margin of the tumor (Fig. 1D). At the end of ablation, EUS revealed an echogenic cloud in the mass. All patients were closely monitored for possible adverse events, including abdominal pain, bleeding, and infection, while maintaining a 24-hour restriction on food. Patients were discharged 2 days after the procedure if no adverse events developed.

Follow-up protocol

The study profile is outlined in Fig. 2. After discharge, patients were followed up every 3 months on an outpatient basis for the first 2 years. The first follow-up contrast-enhanced computed tomography (CECT) was performed at 3 months after the procedure. At 3 months after the first CECT, residual viable tumor was considered present if enhanced areas were noted within the tumors on either the arterial phase or portal venous phase images. CEH-EUS was performed if there was uncertainty concerning the CECT findings regarding whether residual viable tumor was present. Further follow-up CECT was performed at 3-month intervals if an incomplete response was observed on the first follow-up CECT and at 6-month intervals if a complete response was observed on the first follow-up CECT. If a complete response was documented on two consecutive follow-up images, then a yearly follow-up was planned.

Main outcome measurements and definitions of clinical outcomes

The primary purpose of this study was to evaluate the technical feasibility and safety of EUS-guided ethanol injection in patients with p-NETs. The procedure was defined as feasible if the fine needle injection of ethanol inside the tumor was successful. An early adverse event was defined as any procedure-related complication occurring within the first week. A late adverse event was defined as any complications arising at the site of the tumor within 3 months of the procedure. The secondary endpoint was the treatment response rate.

Tumor viability was assessed using CECT and/or CEH-EUS after ablation. CECT/CEH-EUS disclosed a devascularized, hypodense area at the site of ablation (Fig. 1E). CECT was reviewed by an expert radiologist, and an independent observer evaluated the microvasculature and parenchymal perfusion on CEH-EUS. Treatment responses were assessed according to enhanced residual tumor areas on CECT and/or CEH-EUS. Treatment responses were categorized as complete (the disappearance of any enhanced area within the tumors) or incomplete responses (persistence of enhanced tumor). Recurrence was defined as the development of enhancing tumor within the ablation zone and/or the appearance of a new lesion on follow-up CECT and/or CEH-EUS.

RESULTS

Patient characteristics

Eleven patients were enrolled during the study period. The patients and tumor characteristics are described in Table 1. Six patients were women (55%), and the mean age of the patients was 52.5 years (range, 27 to 76). The mean size of the lesion was 12.2 mm (range, 8 to 19), and the most common location was within the head of the pancreas (n=6, 42.9%). The final diagnosis was based on histology and clinical signs as follows: 10 non-functioning neuroendocrine tumors and four insulinomas. Two patients had symptomatic hypoglycemia, and insulinoma was confirmed by biochemical analysis. Multiple tumors were identified in two patients with multiple endocrine neoplasia type 1 syndrome.

The operation could not be performed because of the location of the tumor requiring pancreaticoduodenectomy (n=3), patient refusal (n=4), and underlying comorbidities (n=4).

Feasibility and safety

All patients tolerated the EUS procedure. EUS-guided fine needle injection of ethanol was successfully performed in all 11 patients, who had 14 tumors in total, and a total of 18 treatment sessions were performed (Table 2). For six patients, a single treatment session was performed. Five patients underwent two (n=3) or three (n=2) treatment sessions. Nine patients had solitary pancreatic lesions, and two patients had multiple lesions. Of the latter two patients, one patient had three tumors in the pancreas, and the other had two tumors. The median volume of ethanol injected per treatment session was 1.6 mL (range, 0.5 to 3.8). Multiple injections were performed until ethanol appeared to have been injected throughout the tumor.

The following complications occurred soon after the procedure: mild pancreatitis (n=3) and vague abdominal pain lasting for 1 day (n=1). One patient, who had been previously treated for mild pancreatitis, developed abdominal pain 1 month after the ablation. The patient underwent endoscopic retrograde cholangiopancreatography, which confirmed pancreatic duct stricture requiring stent placement.

Treatment response

Ten patients with 13 tumors were followed up for a median of 370 days (range, 182 to 730) after EUS-guided ethanol fine needle injection, and one patient was lost to follow-up and excluded from the treatment analysis. Treatment responses are summarized in Table 3. A single treatment session resulted in complete tumor ablation at the 3-month radiologic imaging of seven of 13 tumors (response rate, 53.8%). Multiple treatment sessions were performed for three tumors with enhanced residual viable tissue, which increased the number of tumors with a complete response to eight of 13 (response rate, 61.5%). None of these patients developed progressive disease during follow-up. The rate of local complete response was 61.5%. Patients who exhibited incomplete responses after multiple sessions of ethanol ablation received clinical follow-up. Two patients with insulinoma demonstrated the complete absence of hypoglycemic symptoms after treatment.

DISCUSSION

There is growing interest and a need to use ethanol ablation to treat pancreatic lesions. This pilot study demonstrated that EUS-guided ethanol injection for p-NETs appears feasible as a potentially effective treatment with acceptable complication rates.

Ethanol has gained popularity as an ablative agent because it is inexpensive, is readily available, and has the potential to ablate tissue. The mechanism of ethanol ablation involves coagulation necrosis of the tumor as a result of cellular dehydration, protein denaturation, and vascular occlusion.14,15 Matthes et al.16 reported a pilot study of EUS-guided fine needle injection of ethanol into the porcine pancreas, which resulted in localized tissue necrosis without complications. The major limitations of ethanol ablation are the possibility of late recurrence that would require retreatment, incomplete ablation, and the risk of progression during follow-up. It is important to note that complete treatment response in this study was assessed using follow-up enhanced imaging modality rather than histopathologic correlation. Injected ethanol may not always induce complete tumor ablation because of its inhomogeneous distribution within the tumor and its limited effects on extracapsular cancerous spread.17 Physicians should consider the existing potential for residual tumor and progression. EUS-guided ethanol ablation should therefore be reserved for patients who refuse surgery or who are poor surgical candidates. Long-term follow-up study after ablation is needed before patients are considered cured of the disease.

Safety is an important issue in the potential clinical application of EUS-guided ethanol ablation. As with any ablative procedure, the main concern will be the risk of acute pancreatitis, which can result from the dispersion of ethanol outside the lesion and into the surrounding pancreatic parenchyma and/or the main pancreatic duct. A previous animal study that examined ablation of the porcine pancreas using ethanol injections reported that the area of inflammatory change associated with the injected ethanol is concentration-dependent, and local pancreatitis can occur.9 In our study, three cases of mild pancreatitis occurred (27.2%). One patient developed pancreatic duct stricture as a late adverse event. The risk of developing pancreatitis appears to be associated with the total amount of ethanol injected into the tumor during the treatment session; specifically, all procedure-associated cases of pancreatitis occurred when >2 mL of ethanol were administered in a session. Different methods of increasing therapeutic efficacy, as well as avoiding the problems of pancreatitis, should be further explored.

It is difficult to satisfactorily measure the extent of ablation using CECT alone. CEH-EUS is increasingly used for the characterization of solid pancreatic masses.18 Previous research demonstrated that CEH-EUS can be used both to detect p-NET and monitor necrotic areas caused by ethanol ablation.19 In this study, we used CEH-EUS to facilitate the detection of p-NETs and postablation follow-up, and small hypovascular necrotic lesions were clearly observed because of substantial differences (e.g., the absence of contrast flow inside successful ablation sites and the surrounding enhanced normal pancreatic tissues).

Our study has several limitations. The number of patients was small, and the follow-up period may not have been sufficient to identify late tumor recurrence. Another weakness is the uncontrolled, retrospective study design. Nonetheless, our current pilot study is a useful forerunner of a large trial with a long-term follow-up period to fully elucidate the clinical benefits of EUS-guided ethanol ablation for p-NETs.

In conclusion, EUS-guided ethanol ablation is technically feasible and relatively safe, with a 61% treatment response rate in patients with p-NETs. Some improvements in the ablative agent and methodology are needed; however, this minimally invasive procedure could potentially be used to limit local tumor growth in patients who are unsuitable for surgery.

Acknowledgments

This study was supported by a 2013 Weolbong grant from the Korean Gastrointestinal Endoscopy Foundation (2013 Investigation Grant).

Conflicts of Interest: The authors have no financial conflicts of interest.

REFERENCES

1. O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol 2008;34:324–332. 17967523.Article PubMed
2. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61–72. 18177818.Article PubMed
3. Cherenfant J, Stocker SJ, Gage MK, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery 2013;154:785–791. 24074416.Article PubMed
4. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753–781. 16253899.Article PubMed
5. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006;84:196–211. 17312380.Article PubMed
6. Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011;150:75–82. 21683859.Article PubMed
7. Oh HC, Seo DW, Song TJ, et al. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology 2011;140:172–179. 20950614.Article PubMed
8. Larssen TB, Rosendahl K, Horn A, Jensen DK, Rørvik J. Single-session alcohol sclerotherapy in symptomatic benign hepatic cysts performed with a time of exposure to alcohol of 10 min: initial results. Eur Radiol 2003;13:2627–2632. 12955449.Article PubMed
9. Aslanian H, Salem RR, Marginean C, Robert M, Lee JH, Topazian M. EUS-guided ethanol injection of normal porcine pancreas: a pilot study. Gastrointest Endosc 2005;62:723–727. 16246687.Article PubMed
10. Deprez PH, Claessens A, Borbath I, Gigot JF, Maiter D. Successful endoscopic ultrasound-guided ethanol ablation of a sporadic insulinoma. Acta Gastroenterol Belg 2008;71:333–337. 19198582.PubMed
11. Jürgensen C, Schuppan D, Neser F, Ernstberger J, Junghans U, StÖlzel U. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc 2006;63:1059–1062. 16733126.Article PubMed
12. Levy MJ, Thompson GB, Topazian MD, Callstrom MR, Grant CS, Vella A. US-guided ethanol ablation of insulinomas: a new treatment option. Gastrointest Endosc 2012;75:200–206. 22078104.Article PubMed
13. Vleggaar FP, Bij de, Valk GD, Leguit RJ, Siersema PD. Endoscopic ultrasound-guided ethanol ablation of a symptomatic sporadic insulinoma. Endoscopy 2011;43(Suppl 2 UCTN):E328–E329. 22020710.Article PubMed PDF
14. Zhang WY, Li ZS, Jin ZD. Endoscopic ultrasound-guided ethanol ablation therapy for tumors. World J Gastroenterol 2013;19:3397–3403. 23801831.Article PubMed PMC
15. Gelczer RK, Charboneau JW, Hussain S, Brown DL. Complications of percutaneous ethanol ablation. J Ultrasound Med 1998;17:531–533. 9697961.Article PubMed
16. Matthes K, Mino-Kenudson M, Sahani DV, Holalkere N, Brugge WR. Concentration-dependent ablation of pancreatic tissue by EUS-guided ethanol injection. Gastrointest Endosc 2007;65:272–277. 17258986.Article PubMed
17. Lencioni R, Crocetti L, Cioni D, et al. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. J Vasc Interv Radiol 2010;21:1533–1538. 20817558.Article PubMed
18. Kitano M, Sakamoto H, Kudo M. Endoscopic ultrasound: contrast enhancement. Gastrointest Endosc Clin N Am 2012;22:349–358. 22632956.Article PubMed
19. Giday SA, Magno P, Gabrielson KL, et al. The utility of contrast-enhanced endoscopic ultrasound in monitoring ethanol-induced pancreatic tissue ablation: a pilot study in a porcine model. Endoscopy 2007;39:525–529. 17554648.Article PubMed

Fig. 1

(A) Contrast-enhanced computed tomography (CT) scan showing a hypervascular mass in the pancreatic head. (B) Sonographic volumetric analysis of the tumor using 3-dimensional software. (C) Endoscopic ultrasonography-guided puncture of a neuroendocrine tumor. (D) Use of a 22-gauge needle for multiple injections of 99% ethanol until the hyperechoic blush extended to the margin of the tumor. (E) Eight-month follow-up CT scan showing successful ethanol ablation of a tumor.

Fig. 2

Study flowchart. CT, computed tomography; CE-EUS, contrast-enhanced endoscopic ultrasonography; NET, neuroendocrine tumor; EUS-FNA, endoscopic ultrasonography-guided fine-needle aspiration; 3D, 3-dimensional; CECT, contrast-enhanced computed tomography.

Table 1

Baseline Characteristics of the Patients and Tumors

Values are presented as mean±SD, mean±SD (range), or number (%).

EUS-FNI, endoscopic ultrasonography-guided fine needle injection.

Table 2

Procedural Outcomes of Endoscopic Ultrasonography-Guided Ethanol Ablation (Data for the 14 Tumors in the 11 Patients)

Pt, patient; M, male; F, female.

Table 3

Treatment Response after Endoscopic Ultrasonography-Guided Ethanol Ablation (Data for the 14 Tumors in the 11 Patients)

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Portuguese Pancreatic Club Perspectives on Endoscopic Ultrasound-Guided and Surgical Treatment of Pancreatic Neuroendocrine Tumors
Tiago Ribeiro, Sara Castanheira-Rodrigues, Pedro Bastos, Humberto Cristino, Alexandra Fernandes, Eduardo Rodrigues-Pinto, Miguel Bispo, Ricardo Rio-Tinto, Filipe Vilas-Boas
GE - Portuguese Journal of Gastroenterology.2024; 31(4): 225. CrossRef
Endoscopic Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours: An Overview of Proposed Resection and Ablation Techniques
Rocio Chacchi-Cahuin, Edward J. Despott, Nikolaos Lazaridis, Alessandro Rimondi, Giuseppe Kito Fusai, Dalvinder Mandair, Andrea Anderloni, Valentina Sciola, Martyn Caplin, Christos Toumpanakis, Alberto Murino
Cancers.2024; 16(2): 352. CrossRef
A single-center experience on endoscopic ultrasonography-guided ethanol ablation of insulinomas
Zhiyu Yan, Cheng Zhu, Xi Wu, Huijuan Zhu, Tao Yuan, Yaping Luo, Yunlu Feng, Qiang Wang, Shengyu Zhang, Huadan Xue, Zehui Zheng, Aiming Yang
Pancreatology.2023; 23(1): 98. CrossRef
Endoscopic ablation therapy for the pancreatic neoplasms
Kazuyuki Matsumoto, Hironari Kato
Digestive Endoscopy.2023; 35(4): 430. CrossRef
Comparison of EUS-guided ablation and surgical resection for nonfunctioning small pancreatic neuroendocrine tumors: a propensity score–matching study
Hoonsub So, Sung Woo Ko, Seung Hwan Shin, Eun Ha Kim, Jimin Son, SuHyun Ha, Ki Byung Song, Hwa Jung Kim, Myung-Hwan Kim, Do Hyun Park
Gastrointestinal Endoscopy.2023; 97(4): 741. CrossRef
Efficacy and predictive factors of endoscopic ultrasound-guided ethanol ablation in benign solid pancreatic tumors
Jin Ho Choi, Woo Hyun Paik, Sang Hyub Lee, Min Woo Lee, In Rae Cho, Ji Kon Ryu, Yong-Tae Kim
Surgical Endoscopy.2023; 37(8): 5960. CrossRef
Current status of the role of endoscopy in evaluation and management of gastrointestinal and pancreatic neuroendocrine tumors
Zaheer Nabi, Sundeep Lakhtakia, D. Nageshwar Reddy
Indian Journal of Gastroenterology.2023; 42(2): 158. CrossRef
Endoscopic Ultrasound-Guided Local Ablative Therapies for the Treatment of Pancreatic Neuroendocrine Tumors and Cystic Lesions: A Review of the Current Literature
Alexander M. Prete, Tamas A. Gonda
Journal of Clinical Medicine.2023; 12(9): 3325. CrossRef
Performance and Safety of EUS Ablation Techniques for Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Apostolis Papaefthymiou, Gavin J. Johnson, Marcello Maida, Paraskevas Gkolfakis, Daryl Ramai, Antonio Facciorusso, Marianna Arvanitakis, Alexander Ney, Giuseppe K. Fusai, Adrian Saftoiu, Daniela Tabacelia, Simon Phillpotts, Michael H. Chapman, George J. W
Cancers.2023; 15(9): 2627. CrossRef
Evolution of Pancreatic Endotherapy
YongYan Cui, Richard A. Kozarek
Gastrointestinal Endoscopy Clinics of North America.2023; 33(4): 679. CrossRef
An Overview of Pancreatic Neuroendocrine Tumors and an Update on Endoscopic Techniques for Their Management
Osama O. Elkelany, Fred G. Karaisz, Benjamin Davies, Somashekar G. Krishna
Current Oncology.2023; 30(8): 7566. CrossRef
Current status of endoscopic ultrasound (EUS)-guided ablation therapy for pancreatic neuroendocrine neoplasms (PNENs)
Hironari KATO, Kazuyuki MATSUMOTO
Suizo.2023; 38(4): 229. CrossRef
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)
Grigoris Effraimidis, Ulrich Knigge, Maria Rossing, Peter Oturai, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen
Seminars in Cancer Biology.2022; 79: 141. CrossRef
Safety and efficacy of EUS-guided ablation of pancreatic lesions with ethanol versus ethanol with paclitaxel: A systematic review and meta-analysis
SyedMohsin Saghir, BanreetSingh Dhindsa, SaravGunjit Singh Daid, Yassin Naga, Amaninder Dhaliwal, HarmeetS Mashiana, Neil Bhogal, Harlan Sayles, Daryl Ramai, Shailender Singh, Ishfaq Bhat, Rajani Rangray, Stephanie McDonough, DouglasG Adler
Endoscopic Ultrasound.2022; 11(5): 371. CrossRef
Usefulness of contrast‐enhanced endoscopic ultrasonography for the treatment of ethanol reinjection in patient with small pancreatic neuroendocrine neoplasm
Kazuyuki Matsumoto, Hironari Kato, Hiroyuki Okada
Digestive Endoscopy.2022;[Epub] CrossRef
Endotherapy in Pancreatic Diseases
Vaneet Jearth, Surinder S. Rana
Journal of Digestive Endoscopy.2022; 13(01): 019. CrossRef
EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: A systematic review and meta-analysis
Rajat Garg, Abdul Mohammed, Amandeep Singh, MaryP Harnegie, Tarun Rustagi, Tyler Stevens, Prabhleen Chahal
Endoscopic Ultrasound.2022; 11(3): 170. CrossRef
EUS-guided ablation of pancreatic neoplasms
Mihai RIMBAȘ, Gianenrico RIZZATTI, Alberto LARGHI
Minerva Gastroenterology.2022;[Epub] CrossRef
Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are
Roberta Elisa Rossi, Alessandra Elvevi, Camilla Gallo, Andrea Palermo, Pietro Invernizzi, Sara Massironi
World Journal of Gastroenterology.2022; 28(26): 3258. CrossRef
The global research status and trends of the application of endoscopic ultrasonography in pancreatic tumors over the last decades: A bibliometric study
Chuanchao Xia, Hua Yin, Kecheng Zhang, Zhenhuan Wang, Xiaoli Yang, Haojie Huang
Frontiers in Oncology.2022;[Epub] CrossRef
Role of Endoscopic Ultrasound Ablative Therapy in Management of Pancreatic Neuroendocrine Tumors: a Systematic Review
Bharath S, Ashutosh Carpenter, Sanjay Kumar Yadav, Vikesh Agarwal, Uday Somashekhar, Dhananjaya Sharma
Indian Journal of Surgery.2022;[Epub] CrossRef
Role of Endoscopy in Management of Upper Gastrointestinal Cancers
Jeff Liang, Yi Jiang, Yazan Abboud, Srinivas Gaddam
Diseases.2022; 11(1): 3. CrossRef
Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview
Alberto Larghi, Mihai Rimbaș, Gianenrico Rizzatti, Carmine Carbone, Antonio Gasbarrini, Guido Costamagna, Sergio Alfieri, Giampaolo Tortora
Seminars in Oncology.2021; 48(1): 95. CrossRef
Role of Radiofrequency Ablation in the Management of Unresectable Pancreatic Cancer
Muhammad Nadeem Yousaf, Hamid Ehsan, Ahmad Muneeb, Ahsan Wahab, Muhammad K. Sana, Karun Neupane, Fizah S. Chaudhary
Frontiers in Medicine.2021;[Epub] CrossRef
Insulinoma: A Recurrent Pancreatic Tumor Amendable to Computed Tomography–Guided Ethanol-Lipiodol Injection
Himesh B. Zaver, Khaled I. Alnahhal, Hassan Ghoz, Ricardo Paz-Fumagalli, Massimo Raimondo, Frank J. Lukens
ACG Case Reports Journal.2021; 8(2): e00539. CrossRef
Diagnostic Role and Therapeutic Perspectives of Endoscopic Ultrasound for Pancreatic Neuroendocrine Tumor
Jun-Ho Choi
The Korean Journal of Pancreas and Biliary Tract.2021; 26(1): 1. CrossRef
Multiple Endocrine Neoplasia Type 1: Latest Insights
Maria Luisa Brandi, Sunita K Agarwal, Nancy D Perrier, Kate E Lines, Gerlof D Valk, Rajesh V Thakker
Endocrine Reviews.2021; 42(2): 133. CrossRef
Endoscopic Therapy for Pancreatic Benign Neoplasms
Jun Seong Hwang, Sung Woo Ko
Journal of Digestive Cancer Reports.2021; 9(1): 25. CrossRef
It's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1
Aditya S. Shirali, Carolina R. C. Pieterman, Mark A. Lewis, Samuel M. Hyde, Shalini Makawita, Arvind Dasari, Nirav Thosani, Naruhiko Ikoma, Ian E. McCutcheon, Steven G. Waguespack, Nancy D. Perrier
CA: A Cancer Journal for Clinicians.2021; 71(5): 369. CrossRef
Diagnostic and Interventional Role of Endoscopic Ultrasonography for the Management of Pancreatic Neuroendocrine Neoplasms
Giuseppinella Melita, Socrate Pallio, Andrea Tortora, Stefano Francesco Crinò, Antonio Macrì, Gianlorenzo Dionigi
Journal of Clinical Medicine.2021; 10(12): 2638. CrossRef
Study protocol for endoscopic ultrasonography-guided ethanol injection therapy for patients with pancreatic neuroendocrine neoplasm: a multicentre prospective study
Kazuyuki Matsumoto, Hironari Kato, Masayuki Kitano, Kazuo Hara, Masaki Kuwatani, Reiko Ashida, Mamoru Takenaka, Tatsuhiro Yamazaki, Jun Sakurai, Michihiro Yoshida, Hiroyuki Okada
BMJ Open.2021; 11(7): e046505. CrossRef
Surgical outcomes are hampered after endoscopic ultrasonography-guided ethanol lavage and/or Taxol injection in cystic lesions of the pancreas
Seong-Ryong Kim, Song Cheol Kim, Ki Byung Song, Kwang-Min Park, Dae Wook Hwang, Jae Hoon Lee, Sang Hyun Shin, Bong Jun Kwak, Young-Joo Lee
Annals of Hepato-Biliary-Pancreatic Surgery.2021; 25(3): 342. CrossRef
The Role of Contrast-Enhanced Harmonic Endoscopic Ultrasound in Interventional Endoscopic Ultrasound
Cecilia Binda, Chiara Coluccio, Gianmarco Marocchi, Monica Sbrancia, Carlo Fabbri
Medicina.2021; 57(10): 1085. CrossRef
Endoscopic ultrasound-guided ethanol and radiofrequency ablation of pancreatic insulinomas: a systematic literature review
Ghassan El Sayed, Levente Frim, Jamie Franklin, Raymond McCrudden, Charles Gordon, Safa Al-Shamma, Szabolcs Kiss, Péter Hegyi, Bálint Erőss, Péter Jenő Hegyi
Therapeutic Advances in Gastroenterology.2021; 14: 175628482110421. CrossRef
Efficacy and safety of scheduled early endoscopic ultrasonography‐guided ethanol reinjection for patients with pancreatic neuroendocrine tumors: Prospective pilot study
Kazuyuki Matsumoto, Hironari Kato, Seiji Kawano, Hiroyasu Fujiwara, Kenji Nishida, Ryo Harada, Masakuni Fujii, Ryuichi Yoshida, Yuzo Umeda, Shiro Hinotsu, Takahito Yagi, Hiroyuki Okada
Digestive Endoscopy.2020; 32(3): 425. CrossRef
Endoscopic ultrasonography‐guided ethanol ablation of pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 disease following complicated total pancreatectomy
Hsiang‐Hung Lin, Chen‐Wang Chang, Ming‐Jen Chen
Advances in Digestive Medicine.2020; 7(2): 97. CrossRef
EUS‐guided ethanol ablation for small pancreatic neuroendocrine neoplasm
Reiko Ashida
Digestive Endoscopy.2020; 32(3): 326. CrossRef
Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms
Mihai Rimbaş, Mihaela Horumbă, Gianenrico Rizzatti, Stefano Francesco Crinò, Antonio Gasbarrini, Guido Costamagna, Alberto Larghi
Digestive Endoscopy.2020; 32(7): 1031. CrossRef
The safety and efficacy of endoscopic ultrasound-guided ablation therapy for solid pancreatic tumors: a systematic review
Lu Zhang, Shali Tan, Shu Huang, Chunyu Zhong, Muhan Lü, Yan Peng, Xiaowei Tang
Scandinavian Journal of Gastroenterology.2020; 55(9): 1121. CrossRef
Surgical Management of Neuroendocrine Tumours of the Pancreas
Regis Souche, Christian Hobeika, Elisabeth Hain, Sebastien Gaujoux
Journal of Clinical Medicine.2020; 9(9): 2993. CrossRef
Recent developments in endoscopic ultrasound-guided ablation treatment
Hoonsub So, Dongwook Oh, Dong-Wan Seo
International Journal of Gastrointestinal Intervention.2020; 9(4): 135. CrossRef
Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasound for the Guidance and Monitoring of Endoscopic Radiofrequency Ablation
Jun-Ho Choi, Dong-Wan Seo, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim
Gut and Liver.2020; 14(6): 826. CrossRef
Treatment of Insulinomas with Minimally Invasive Physical Procedure. Literature Review
Stanislav V. Berelavichus, Andrey G. Kriger, Rimma S. Dugarova, Ayrat R. Kaldarov
SN Comprehensive Clinical Medicine.2019; 1(2): 104. CrossRef
Current Status of Endoscopic Ultrasound Techniques for Pancreatic Neoplasms
Yousuke Nakai, Naminatsu Takahara, Suguru Mizuno, Hirofumi Kogure, Kazuhiko Koike
Clinical Endoscopy.2019; 52(6): 527. CrossRef
Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows
Alessandra Zilli, Paolo Giorgio Arcidiacono, Dario Conte, Sara Massironi
Digestive and Liver Disease.2018; 50(1): 6. CrossRef
Outcomes after endoscopic ultrasound‐guided ethanol‐lipiodol ablation of small pancreatic neuroendocrine tumors
Jun‐Ho Choi, Do Hyun Park, Myung‐Hwan Kim, Hee Sang Hwang, Seung‐Mo Hong, Tae Jun Song, Sang Soo Lee, Dong‐Wan Seo, Sung Koo Lee
Digestive Endoscopy.2018; 30(5): 652. CrossRef
Endoscopic Management of Pancreatobiliary Neoplasms
Andrew Y. Wang, Patrick S. Yachimski
Gastroenterology.2018; 154(7): 1947. CrossRef
Future Perspectives on Endoscopic Ultrasonography-Guided Therapy for Pancreatic Neoplasm
Woo Hyun Paik, Sang Hyub Lee, Sunguk Jang
Clinical Endoscopy.2018; 51(3): 229. CrossRef
Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies
Lingaku Lee, Tetsuhide Ito, Robert T. Jensen
Expert Review of Anticancer Therapy.2018; 18(9): 837. CrossRef
Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound–Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated
Hee Sang Hwang, YunJae Kim, Soyeon An, Sung Joo Kim, Joo Young Kim, Sang-Yeob Kim, Dae Wook Hwang, Do Hyun Park, Sang Soo Lee, Song Cheol Kim, Dong-Wan Seo, Seung-Mo Hong
Pancreas.2018; 47(10): 1296. CrossRef
Endoscopic ultrasonography‐guided tumor ablation
Sundeep Lakhtakia, Dong‐Wan Seo
Digestive Endoscopy.2017; 29(4): 486. CrossRef
Endoscopic Ultrasound-Guided Direct Intervention for Solid Pancreatic Tumors
Jimin Han, Kenneth J. Chang
Clinical Endoscopy.2017; 50(2): 126. CrossRef
Small pancreatic insulinoma: Successful endoscopic ultrasound‐guided radiofrequency ablation in a single session using a 22‐G fine needle
Francesc Bas‐Cutrina, Domingo Bargalló, Joan B. Gornals
Digestive Endoscopy.2017; 29(5): 636. CrossRef
Echoendoscopic ablative therapy for solid pancreatic tumors
Woo Hyun Paik, Dong Wan Seo
Journal of Digestive Diseases.2017; 18(3): 135. CrossRef
Recent Advances in Therapeutic Endosonography for Cancer Treatment
Saurabh Mukewar, Venkataraman Raman Muthusamy
Gastrointestinal Endoscopy Clinics of North America.2017; 27(4): 657. CrossRef
Endoscopic ultrasound guided tumor directed therapy and cyst ablation
Seyfettin Koklu, Omer Basar, William R. Brugge
Techniques in Gastrointestinal Endoscopy.2017; 19(4): 219. CrossRef
Therapy of Pancreatic Neuroendocrine Tumors: Fine Needle Intervention including Ethanol and Radiofrequency Ablation
Sundeep Lakhtakia
Clinical Endoscopy.2017; 50(6): 546. CrossRef
Diagnosis of Pancreatic Neuroendocrine Tumors
Dong Wook Lee, Michelle Kang Kim, Ho Gak Kim
Clinical Endoscopy.2017; 50(6): 537. CrossRef
Minimally Invasive Techniques for Resection of Pancreatic Neuroendocrine Tumors
Gustavo G. Fernandez Ranvier, Daniel Shouhed, William B. Inabnet
Surgical Oncology Clinics of North America.2016; 25(1): 195. CrossRef
Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors
Michail Papamichail, Amir Ali, Michail Pizanias, Praveen Peddu, John Karani, Nigel Heaton
Korean Journal of Hepato-Biliary-Pancreatic Surgery.2016; 20(3): 116. CrossRef
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
Tetsuhide Ito, Lingaku Lee, Robert T. Jensen
Expert Opinion on Pharmacotherapy.2016; 17(16): 2191. CrossRef
Endoscopic Ultrasonography-Guided Ethanol Injection for a Pancreatic Neuroendocrine Tumor with Multiple Endocrine Neoplasia Type 1
Sujong An, Jae Yong Lee, Sung-ha Hwang, Do Hyun Park, Sung-Koo Lee
Korean Journal of Pancreas and Biliary Tract.2016; 21(4): 202. CrossRef
Interventional Therapy for Pancreatic Cancer
Jianwei Zhu, Zhendong Jin
Gastrointestinal Tumors.2016; 3(2): 81. CrossRef
The Expanding Role of Contrast-Enhanced Endoscopic Ultrasound in Pancreatobiliary Disease
Jun-Ho Choi, Dong Wan Seo
Gut and Liver.2015; 9(6): 707. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Endoscopic Ultrasonography-Guided Ethanol Ablation for Small Pancreatic Neuroendocrine Tumors: Results of a Pilot Study

Clin Endosc. 2015;48(2):158-164. Published online March 27, 2015

DOI: https://doi.org/10.5946/ce.2015.48.2.158

XML Download

Figure

Related articles

Endoscopic Ultrasonography-Guided Ethanol Ablation for Small Pancreatic Neuroendocrine Tumors: Results of a Pilot Study

Fig. 1 (A) Contrast-enhanced computed tomography (CT) scan showing a hypervascular mass in the pancreatic head. (B) Sonographic volumetric analysis of the tumor using 3-dimensional software. (C) Endoscopic ultrasonography-guided puncture of a neuroendocrine tumor. (D) Use of a 22-gauge needle for multiple injections of 99% ethanol until the hyperechoic blush extended to the margin of the tumor. (E) Eight-month follow-up CT scan showing successful ethanol ablation of a tumor.

Fig. 2 Study flowchart. CT, computed tomography; CE-EUS, contrast-enhanced endoscopic ultrasonography; NET, neuroendocrine tumor; EUS-FNA, endoscopic ultrasonography-guided fine-needle aspiration; 3D, 3-dimensional; CECT, contrast-enhanced computed tomography.

Fig. 1

Fig. 2

Endoscopic Ultrasonography-Guided Ethanol Ablation for Small Pancreatic Neuroendocrine Tumors: Results of a Pilot Study

Table 1

Baseline Characteristics of the Patients and Tumors

Values are presented as mean±SD, mean±SD (range), or number (%).

EUS-FNI, endoscopic ultrasonography-guided fine needle injection.

Table 2

Procedural Outcomes of Endoscopic Ultrasonography-Guided Ethanol Ablation (Data for the 14 Tumors in the 11 Patients)

Pt, patient; M, male; F, female.

Table 3

Treatment Response after Endoscopic Ultrasonography-Guided Ethanol Ablation (Data for the 14 Tumors in the 11 Patients)

Table 1 Baseline Characteristics of the Patients and Tumors

Values are presented as mean±SD, mean±SD (range), or number (%).

EUS-FNI, endoscopic ultrasonography-guided fine needle injection.

Table 2 Procedural Outcomes of Endoscopic Ultrasonography-Guided Ethanol Ablation (Data for the 14 Tumors in the 11 Patients)

Pt, patient; M, male; F, female.

Table 3 Treatment Response after Endoscopic Ultrasonography-Guided Ethanol Ablation (Data for the 14 Tumors in the 11 Patients)